Global Etoricoxib Intermediate Report Thumbnail

Global Etoricoxib Intermediate Market by Type (n-House Manufacturing, Contract Manufacturing Organizations), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis, Chronic Low Back Pain, Acute Pain, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: PH-3515
  • Author: Up Market Research
  • Rating: 4.8
  • Total Reviews: 94
  • No. Of Pages: 230
  • Format:
  • Pub. Date: 2021-03-01
  • Share:

Up Market Research published a new report titled “Etoricoxib Intermediate Market research report which is segmented by Types (n-House Manufacturing, Contract Manufacturing Organizations), By Applications (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis, Chronic Low Back Pain, Acute Pain, Others), By Players/Companies Bayer, Novacap, Abbott, Pfizer, Geri-Care, Perrigo, Kopran, Merck, Sun Pharmaceutical, GlaxoSmithKline”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

Report AttributesReport Details
Report TitleEtoricoxib Intermediate Market Research Report
By Typen-House Manufacturing, Contract Manufacturing Organizations
By ApplicationRheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis, Chronic Low Back Pain, Acute Pain, Others
By CompaniesBayer, Novacap, Abbott, Pfizer, Geri-Care, Perrigo, Kopran, Merck, Sun Pharmaceutical, GlaxoSmithKline
Regions CoveredNorth America, Europe, APAC, Latin America, MEA
Base Year2020
Historical Year2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year2028
Number of Pages230
Number of Tables & Figures161
Customization AvailableYes, the report can be customized as per your need.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Etoricoxib Intermediate Industry Outlook

Global Etoricoxib Intermediate Market Report Segments:

The market is segmented by Type n-House Manufacturing, Contract Manufacturing Organizations and By Application Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis, Chronic Low Back Pain, Acute Pain, Others.

Some of the companies that are profiled in this report are:

  1. Bayer
  2. Novacap
  3. Abbott
  4. Pfizer
  5. Geri-Care
  6. Perrigo
  7. Kopran
  8. Merck
  9. Sun Pharmaceutical
  10. GlaxoSmithKline

Etoricoxib Intermediate Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Etoricoxib Intermediate Market

Overview of the regional outlook of the Etoricoxib Intermediate Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Etoricoxib Intermediate Market Overview

Highlights of The Etoricoxib Intermediate Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Etoricoxib Intermediate Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. n-House Manufacturing

                2. Contract Manufacturing Organizations

       7. By Application:

                1. Rheumatoid Arthritis

                2. Psoriatic Arthritis

                3. Osteoarthritis

                4. Ankylosing Spondylitis

                5. Chronic Low Back Pain

                6. Acute Pain

                7. Others

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Etoricoxib Intermediate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Etoricoxib Intermediate Market Statistics

Reasons to Purchase the Etoricoxib Intermediate Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Etoricoxib Intermediate Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Etoricoxib Intermediate Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Etoricoxib Intermediate Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Etoricoxib Intermediate Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Etoricoxib Intermediate Market Size & Forecast, 2018-2028 
      4.5.1 Etoricoxib Intermediate Market Size and Y-o-Y Growth 
      4.5.2 Etoricoxib Intermediate Market Absolute $ Opportunity 

Chapter 5 Global Etoricoxib Intermediate Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Etoricoxib Intermediate Market Size Forecast by Type
      5.2.1 n-House Manufacturing
      5.2.2 Contract Manufacturing Organizations
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Etoricoxib Intermediate Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Etoricoxib Intermediate Market Size Forecast by Applications
      6.2.1 Rheumatoid Arthritis
      6.2.2 Psoriatic Arthritis
      6.2.3 Osteoarthritis
      6.2.4 Ankylosing Spondylitis
      6.2.5 Chronic Low Back Pain
      6.2.6 Acute Pain
      6.2.7 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Etoricoxib Intermediate Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Etoricoxib Intermediate Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Etoricoxib Intermediate Analysis and Forecast
   9.1 Introduction
   9.2 North America Etoricoxib Intermediate Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Etoricoxib Intermediate Market Size Forecast by Type
      9.6.1 n-House Manufacturing
      9.6.2 Contract Manufacturing Organizations
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Etoricoxib Intermediate Market Size Forecast by Applications
      9.10.1 Rheumatoid Arthritis
      9.10.2 Psoriatic Arthritis
      9.10.3 Osteoarthritis
      9.10.4 Ankylosing Spondylitis
      9.10.5 Chronic Low Back Pain
      9.10.6 Acute Pain
      9.10.7 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Etoricoxib Intermediate Analysis and Forecast
   10.1 Introduction
   10.2 Europe Etoricoxib Intermediate Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Etoricoxib Intermediate Market Size Forecast by Type
      10.6.1 n-House Manufacturing
      10.6.2 Contract Manufacturing Organizations
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Etoricoxib Intermediate Market Size Forecast by Applications
      10.10.1 Rheumatoid Arthritis
      10.10.2 Psoriatic Arthritis
      10.10.3 Osteoarthritis
      10.10.4 Ankylosing Spondylitis
      10.10.5 Chronic Low Back Pain
      10.10.6 Acute Pain
      10.10.7 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Etoricoxib Intermediate Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Etoricoxib Intermediate Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Etoricoxib Intermediate Market Size Forecast by Type
      11.6.1 n-House Manufacturing
      11.6.2 Contract Manufacturing Organizations
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Etoricoxib Intermediate Market Size Forecast by Applications
      11.10.1 Rheumatoid Arthritis
      11.10.2 Psoriatic Arthritis
      11.10.3 Osteoarthritis
      11.10.4 Ankylosing Spondylitis
      11.10.5 Chronic Low Back Pain
      11.10.6 Acute Pain
      11.10.7 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Etoricoxib Intermediate Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Etoricoxib Intermediate Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Etoricoxib Intermediate Market Size Forecast by Type
      12.6.1 n-House Manufacturing
      12.6.2 Contract Manufacturing Organizations
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Etoricoxib Intermediate Market Size Forecast by Applications
      12.10.1 Rheumatoid Arthritis
      12.10.2 Psoriatic Arthritis
      12.10.3 Osteoarthritis
      12.10.4 Ankylosing Spondylitis
      12.10.5 Chronic Low Back Pain
      12.10.6 Acute Pain
      12.10.7 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Etoricoxib Intermediate Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Etoricoxib Intermediate Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Etoricoxib Intermediate Market Size Forecast by Type
      13.6.1 n-House Manufacturing
      13.6.2 Contract Manufacturing Organizations
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Etoricoxib Intermediate Market Size Forecast by Applications
      13.10.1 Rheumatoid Arthritis
      13.10.2 Psoriatic Arthritis
      13.10.3 Osteoarthritis
      13.10.4 Ankylosing Spondylitis
      13.10.5 Chronic Low Back Pain
      13.10.6 Acute Pain
      13.10.7 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Etoricoxib Intermediate Market: Competitive Dashboard
   14.2 Global Etoricoxib Intermediate Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Bayer
      14.3.2 Novacap
      14.3.3 Abbott
      14.3.4 Pfizer
      14.3.5 Geri-Care
      14.3.6 Perrigo
      14.3.7 Kopran
      14.3.8 Merck
      14.3.9 Sun Pharmaceutical
      14.3.10 GlaxoSmithKline
Segments Covered in the Report
The global Etoricoxib Intermediate market has been segmented based on

By Types
  • n-House Manufacturing
  • Contract Manufacturing Organizations
By Applications
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Chronic Low Back Pain
  • Acute Pain
  • Others
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Bayer
  • Novacap
  • Abbott
  • Pfizer
  • Geri-Care
  • Perrigo
  • Kopran
  • Merck
  • Sun Pharmaceutical
  • GlaxoSmithKline

Buy Report